Literature DB >> 698608

Interstitial lung disease in a patient treated with 5-fluorouracil and mitomycin C.

J W Fielding, R A Stockley, V S Brookes.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 698608      PMCID: PMC1607549          DOI: 10.1136/bmj.2.6137.602

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  4 in total

1.  A-a difference in O2 tension and physiological dead space in normal man.

Authors:  J M RAINE; J M BISHOP
Journal:  J Appl Physiol       Date:  1963-03       Impact factor: 3.531

2.  A clinical review of bleomycin--a new antineoplastic agent.

Authors:  R H Blum; S K Carter; K Agre
Journal:  Cancer       Date:  1973-04       Impact factor: 6.860

3.  Nonbacterial pneumonitis with multidrug antineoplastic therapy in breast carcinoma.

Authors:  F H Stutz; D C Tormey; J Blom
Journal:  Can Med Assoc J       Date:  1973-03-17       Impact factor: 8.262

4.  Cytotoxic drug-induced lung disease.

Authors:  H D Sostman; R A Matthay; C E Putman
Journal:  Am J Med       Date:  1977-04       Impact factor: 4.965

  4 in total
  4 in total

Review 1.  Lung damage from cytotoxic drugs.

Authors:  C H Collis
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

2.  Experimental bleomycin lung in mice. A contribution to the pathogenesis of pulmonary fibrosis.

Authors:  E Fasske; K Morgenroth
Journal:  Lung       Date:  1983       Impact factor: 2.584

3.  Interstitial lung disease secondary to Cetuximab in bladder cancer: an Oncologist's perspective.

Authors:  Louise Price; Patricia Glynn; Anjali Zarkar
Journal:  BMJ Case Rep       Date:  2017-12-20

4.  Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.

Authors:  J Crocker; E L Jones
Journal:  J Clin Pathol       Date:  1983-01       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.